Synopsys upgraded by Bank of America on strong 2026 guidance

Bank of America upgraded Synopsys to Buy from Neutral and raised its price target to $560 from $500 (vs. current ~ $478), citing stronger-than-expected fiscal 2026 guidance and reduced China/Intel risk; the company guided fiscal 2026 revenue to $9.6 billion (including $2.9 billion from recently acquired Ansys) and implied roughly 8% core Synopsys revenue growth, prompting BofA to raise EPS estimates to $14.27 for FY26 and $17 for FY27. The bank views Synopsys as an “attractive lower‑beta AI‑levered” play supported by recurring chip‑design revenue and R&D spending, and flags potential upside if Intel wins foundry business, joint Ansys products gain traction, or China rebounds. Key risks include uncertainty in IP recovery, Ansys seasonality and significant integration work/costs from the ~$35 billion Ansys acquisition, and BofA still prefers Cadence as its top EDA pick due to stronger margins and a healthier balance sheet.

Analysis

Bank of America upgraded Synopsys to Buy from Neutral and raised its price target to $560 from $500, citing fiscal 2026 guidance that exceeded expectations; the stock trades around $478. Management guided fiscal 2026 revenue to $9.6 billion including $2.9 billion from the Ansys acquisition, and BofA raised EPS estimates to $14.27 for FY26 and $17 for FY27 despite a higher tax rate, which the bank interprets as improved earnings visibility.

The guidance implies roughly 8% year‑over‑year growth for core Synopsys and supports BofA’s characterization of the company as an “attractive lower‑beta AI‑levered” exposure backed by recurring chip‑design revenue and R&D spend. BofA flags upside catalysts including additional Intel foundry customers, traction for joint Synopsys‑Ansys products, and a potential China rebound after a 22% decline in fiscal 2024, all of which could accelerate revenue and margin improvement.

Key near‑term risks include uncertainty in the recovery of Synopsys’ IP segment, seasonal revenue swings at Ansys, and substantial integration work from the ~$35 billion Ansys acquisition that could increase near‑term integration costs and compress margins. BofA still prefers Cadence as its sector top pick due to stronger margins, share‑gain potential and a less leveraged balance sheet, suggesting relative exposure decisions should weigh balance‑sheet and margin resilience.

Key Decisions for Investors

• Consider a measured increase in Synopsys exposure given BofA’s upgrade and $560 target versus the current ~$478 price, but size positions conservatively to reflect integration and IP recovery risk
• Monitor three near‑term catalysts—Intel foundry customer wins, early commercial traction of Synopsys‑Ansys joint products, and sequential stabilization in China—and use those data points as triggers to add to or reduce positions
• Maintain a relative allocation bias toward Cadence if priority is margin resilience and lower leverage, and consider hedges or position limits on Synopsys until integration costs and Ansys seasonality prove manageable